---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-23-000018"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:20:32.514227+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Moderna Q1 revenue $1.9B, net income $79M, reiterates $5B FY sales guidance

## Summary
- Q1 revenue $1.9B (down 69% YoY); GAAP net income $79M ($0.19 EPS) vs $3.7B ($8.58 EPS) in Q1 2022.
- Cost of sales 43% of product sales vs 17% prior year; includes $148M inventory write-downs and $135M idle capacity charges.
- R&D spending surged 104% to $1.1B, driven by RSV, flu, CMV programs; total 2023 OpEx guided ~$6B.
- RSV vaccine (mRNA-1345) met primary endpoint in older adults; expects regulatory submission and 2024 launch.
- COVID-19 vaccine sales from APAs still projected at $5B for 2023; Q2 sales expected $0.2-0.3B.

## SEC filing metadata
- accession: 0001682852-23-000018
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000018/0001682852-23-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000018/mrna-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-23-000018
- JSON: https://secwatch.observer/filing/0001682852-23-000018.json
- Plain text: https://secwatch.observer/filing/0001682852-23-000018.txt

## Key facts
- Earnings Releases
  Moderna, Inc. reported the first quarter of 2023 results: revenue $1.9 billion, net income $79 million, EPS $0.19. Guidance reaffirmed.
  - Period: the first quarter of 2023
  - Revenue: $1.9 billion
  - Net income: $79 million
  - EPS: $0.19
  - Guidance: reaffirmed
  - Result: reported results
  source text: Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates First quarter 2023 revenues of $1.9 billion; GAAP net income of $79 million and GAAP diluted EPS of $0.19
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000018/0001682852-23-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.